Stern Anat, Papanicolaou Genovefa A
Infectious Disease Service, Memorial Sloan Kettering Cancer Center, NY1250 1st Avenue, New York, NY, 10065, USA.
Curr Infect Dis Rep. 2019 Nov 15;21(11):45. doi: 10.1007/s11908-019-0699-0.
Transplant recipients are at risk for cytomegalovirus (CMV) infection and associated morbidity and mortality. We summarize recently introduced or currently investigated modalities for prevention and treatment of CMV infection in hematopoietic cell (HCT) and solid organ transplant (SOT) recipients.
Letermovir was recently approved for CMV prevention in HCT recipients. Data from real world studies support its role to improve outcomes in this population. Letermovir is currently under investigation for broader patient populations and indications. Maribavir is in late stages of development for CMV treatment and may provide a safer alternative to currently available anti-CMV drugs. Promising CMV vaccine candidates and adoptive cell therapy approaches are under evaluation. CMV immune monitoring assays are predicted to play a more central role in our clinical decision making. In recent years, major advances have been made in CMV prevention and treatment in transplant recipients. Rigorous research is ongoing and is anticipated to further impact our ability to improve outcomes in this population.
移植受者有感染巨细胞病毒（CMV）的风险，并伴有相关的发病率和死亡率。我们总结了最近引入或目前正在研究的预防和治疗造血细胞移植（HCT）和实体器官移植（SOT）受者CMV感染的方法。
来特莫韦最近被批准用于预防HCT受者的CMV感染。来自真实世界研究的数据支持其在改善该人群预后方面的作用。来特莫韦目前正在针对更广泛的患者群体和适应症进行研究。玛巴洛沙韦正处于CMV治疗的后期开发阶段，可能为目前可用的抗CMV药物提供更安全的替代方案。有前景的CMV候选疫苗和过继性细胞治疗方法正在评估中。预计CMV免疫监测检测将在我们的临床决策中发挥更核心的作用。近年来，移植受者的CMV预防和治疗取得了重大进展。严格的研究正在进行，预计将进一步影响我们改善该人群预后的能力。
